BACKGROUND AND PURPOSE: The antipyretic and hypothermic prodrug dipyrone prevents PGE2 -dependent and -independent fever induced by LPS from Escherichia coli and Tityus serrulatus venom (Tsv) respectively. We aimed to identify the dipyrone metabolites responsible for the antipyretic and hypothermic effects. EXPERIMENTAL APPROACH: Male Wistar rats were treated i.p. with indomethacin (2 mg·kg(-1) ), dipyrone, 4-methylaminoantipyrine (4-MAA), 4-aminoantipyrine (4-AA) (60-360 mg·kg(-1) ), 4-formylaminoantipyrine, 4-acethylaminoantipyrine (120-360 mg·kg(-1) ) or vehicle 30 min before i.p. injection of LPS (50 μg·kg(-1) ), Tsv (150 μg·kg(-1) ) or saline. Rectal temperatures were measured by tele-thermometry and dipyrone metabolite concentrations determined in the plasma, CSF and hypothalamus by LC-MS/MS. PGE2 concentrations were determined in the CSF and hypothalamus by elisa. KEY RESULTS: In contrast to LPS, Tsv-induced fever was not followed by increased PGE2 in the CSF or hypothalamus. The antipyretic time-course of 4-MAA and 4-AA on LPS-induced fever overlapped with the period of the highest concentrations of 4-MAA and 4-AA in the hypothalamus, CSF and plasma. These metabolites reduced LPS-induced fever and the PGE2 increase in the plasma, CSF and hypothalamus. Only 4-MAA inhibited Tsv-induced fever. The higher doses of dipyrone and 4-MAA also induced hypothermia. CONCLUSIONS AND IMPLICATIONS: The presence of 4-MAA and 4-AA in the CSF and hypothalamus was associated with PGE2 synthesis inhibition and a decrease in LPS-induced fever. 4-MAA was also shown to be an antipyretic metabolite for PGE2 -independent fever induced by Tsv suggesting that it is responsible for the additional antipyretic mechanism of dipyrone. Moreover, 4-MAA is the hypothermic metabolite of dipyrone.
BACKGROUND AND PURPOSE: The antipyretic and hypothermic prodrug dipyrone prevents PGE2 -dependent and -independent fever induced by LPS from Escherichia coli and Tityus serrulatus venom (Tsv) respectively. We aimed to identify the dipyrone metabolites responsible for the antipyretic and hypothermic effects. EXPERIMENTAL APPROACH: Male Wistar rats were treated i.p. with indomethacin (2 mg·kg(-1) ), dipyrone, 4-methylaminoantipyrine (4-MAA), 4-aminoantipyrine (4-AA) (60-360 mg·kg(-1) ), 4-formylaminoantipyrine, 4-acethylaminoantipyrine (120-360 mg·kg(-1) ) or vehicle 30 min before i.p. injection of LPS (50 μg·kg(-1) ), Tsv (150 μg·kg(-1) ) or saline. Rectal temperatures were measured by tele-thermometry and dipyrone metabolite concentrations determined in the plasma, CSF and hypothalamus by LC-MS/MS. PGE2 concentrations were determined in the CSF and hypothalamus by elisa. KEY RESULTS: In contrast to LPS, Tsv-induced fever was not followed by increased PGE2 in the CSF or hypothalamus. The antipyretic time-course of 4-MAA and 4-AA on LPS-induced fever overlapped with the period of the highest concentrations of 4-MAA and 4-AA in the hypothalamus, CSF and plasma. These metabolites reduced LPS-induced fever and the PGE2 increase in the plasma, CSF and hypothalamus. Only 4-MAA inhibited Tsv-induced fever. The higher doses of dipyrone and 4-MAA also induced hypothermia. CONCLUSIONS AND IMPLICATIONS: The presence of 4-MAA and 4-AA in the CSF and hypothalamus was associated with PGE2 synthesis inhibition and a decrease in LPS-induced fever. 4-MAA was also shown to be an antipyretic metabolite for PGE2 -independent fever induced by Tsv suggesting that it is responsible for the additional antipyretic mechanism of dipyrone. Moreover, 4-MAA is the hypothermic metabolite of dipyrone.
Authors: Fernando A Aguiar; David do C Malvar; Artur de L L Vaz; Leandro A Calixto; Giuliano C Clososki; Cristiane M de Gaitani; Glória E P de Souza; Valquíria A P Jabor Journal: Bioanalysis Date: 2013-11 Impact factor: 2.681
Authors: Juliano M Martins; Daniela T Longhi-Balbinot; Denis M Soares; Maria José Figueiredo; David do C Malvar; Miriam C C de Melo; Giles A Rae; Glória E P Souza Journal: J Appl Physiol (1985) Date: 2012-08-30
Authors: Aline S C Fabricio; Giuseppe Tringali; Giacomo Pozzoli; Miriam C Melo; Juliana A Vercesi; Gloria E P Souza; Pierluigi Navarra Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-02-02 Impact factor: 3.619
Authors: Tobias Rogosch; Christian Sinning; Agnes Podlewski; Bernhard Watzer; Joel Schlosburg; Aron H Lichtman; Maria G Cascio; Tiziana Bisogno; Vincenzo Di Marzo; Rolf Nüsing; Peter Imming Journal: Bioorg Med Chem Date: 2011-11-25 Impact factor: 3.641
Authors: Francielli C C Melo; Renata P Alves; Anderson L Valle; Fabiana de A A Santos; Ana Carolina S Dias; Isabela M B Goulart; Eduardo G A Oliveira; Guedmiller S Oliveira; Luciano P Rodrigues; Luiz R Goulart Journal: Sensors (Basel) Date: 2022-05-12 Impact factor: 3.847
Authors: Mansour Sobeh; Samar Rezq; Mohammed Cheurfa; Mohamed A O Abdelfattah; Rasha M H Rashied; Assem M El-Shazly; Abdelaziz Yasri; Michael Wink; Mona F Mahmoud Journal: Biomolecules Date: 2020-04-13